Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prrv.2012.08.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges in treating patients with comorbid asthma and bronchiectasis.
Respir Med
January 2025
Department of Internal Medicine ASL Salerno, 'Santa Maria della Speranza', Hospital, Salerno, Italy; Postgraduate Program in Allergy and Clinical Immunology, University of Naples 'Federico II', Naples, Italy.
The management of patients with overlapping asthma and bronchiectasis requires a tailored approach, starting with a comprehensive assessment of the patient's clinical profile, including the severity of asthma and the extent of bronchiectasis. Inhaled corticosteroids (ICS) are often recommended, but their use should be carefully monitored because of the risk of increased infection. If the asthma is well controlled and the bronchiectasis remains stable, a gradual reduction in the dose of ICS may be considered.
View Article and Find Full Text PDFRegular versus as-needed treatments for mild asthma in children, adolescents, and adults: a systematic review and network meta-analysis.
BMC Med
January 2025
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
Background: Inhaled corticosteroids (ICS) are recommended treatment for mild asthma. We aimed to update the evidence on the efficacy and safety of ICS-containing regimens, leukotriene receptor antagonists (LTRA), and tiotropium relative to as-needed (AN) short-acting β2-agonists (SABA) in children (aged 6-11 years) and adolescents/adults.
Methods: A systematic review of randomized controlled trials (RCTs) of regular and AN treatment for mild asthma was conducted (CRD42022352384).
The effect of allergic rhinitis treatment on asthma control: a systematic review.
NPJ Prim Care Respir Med
January 2025
Erasmus MC, Department of General Practice, Rotterdam, The Netherlands.
Asthma and allergic rhinitis (AR) are common disorders of the respiratory tract that often coincide. Control of AR symptoms can improve asthma outcomes in patients with co-existing diseases. Our aim is to produce a systematic review of the effectiveness of conventional anti-AR medication for asthma outcomes in patients with both diseases.
View Article and Find Full Text PDFA retrospective study on potential drug‒drug interactions in patients with severe asthma receiving biological therapy: a single-center experience.
BMC Pulm Med
January 2025
Clinic for Lung Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia.
Background: Prevalence of potential drug-drug interactions (pDDIs) in adult patients with severe asthma on biological therapy and their clinical significance have not been fully addressed, thus the aim of this study was to investigate them.
Methods: In this retrospective observational study, patients who were diagnosed with severe asthma and to whom biological therapy was prescribed between September 2015 and December 2020, were enrolled. The study was conducted at the Department of Allergic and Obstructive Pulmonary Diseases, Clinic for Lung Diseases Jordanovac, Clinical Hospital Center Zagreb.
Alpha-Lipoic Acid-Mediated Inhibition of LTB Synthesis Suppresses Epithelial-Mesenchymal Transition, Modulating Functional and Tumorigenic Capacities in Non-Small Cell Lung Cancer A549 Cells.
Curr Ther Res Clin Exp
November 2024
Laboratorio de Oncología Celular y Molecular. Departamento de Oncología Básico-Clínica. Facultad de Medicina. Universidad de Chile, Santiago, Chile.
Background: Leukotriene B (LTB) plays a crucial role in carcinogenesis by inducing epithelial-mesenchymal transition (EMT), a process associated with tumor progression. The synthesis of LTB is mediated by leukotriene A hydrolase (LTAH), and it binds to the receptors BLT and BLT. Dysregulation in LTB production is linked to the development of various pathologies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!